Department of Pharmacology and Medicine, Division of Clinical Pharmacology, Rush University, Chicago, IL, USA.
Am J Ther. 2009 Jan-Feb;16(1):98-101. doi: 10.1097/MJT.0b013e318196082e.
The development of edematous states is usually due to heart failure, renal failure, hepatic failure, or a combination of these conditions. Although the number of patients with edema and ascites due to hepatic cirrhosis or renal failure is less frequent than with congestive heart failure, the treatment of these conditions is often difficult. Although diuretic therapy is often employed, effective reduction in edema or ascites may be difficult to achieve and is associated with significant side effects including hyponatremia, hypotension, and a further decrease in renal function. Aggressive diuretic therapy of ascites may result in hepatic encephalopathy or hepatorenal syndrome. Each condition needs to be evaluated, and an optimum therapeutic approach needs to be devised. This article provides a review of the challenges and therapeutic approaches for the treatment of these conditions and provides a review of new therapies on the horizon that may be promising.
水肿状态的发展通常是由于心力衰竭、肾衰竭、肝功能衰竭或这些情况的组合引起的。虽然由于肝硬化或肾衰竭导致水肿和腹水的患者数量比充血性心力衰竭患者少,但这些情况的治疗往往很困难。尽管常采用利尿剂治疗,但有效减少水肿或腹水可能很难实现,并且会伴有显著的副作用,包括低钠血症、低血压和肾功能进一步下降。腹水的积极利尿剂治疗可能导致肝性脑病或肝肾综合征。需要对每种病症进行评估,并设计出最佳的治疗方法。本文综述了治疗这些病症的挑战和治疗方法,并对新的治疗方法进行了综述,这些新的治疗方法可能具有前景。